Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trial.
Ze-Guang Zheng, Wu-Zhuang Sun, Jie-Ying Hu, Zhi-Jun Jie, Jin-Fu Xu, Jie Cao, Yuan-Lin Song, Chang-Hui Wang, Jing Wang, Hui Zhao, Zhong-Liang Guo, Nan-Shan Zhong · Respiratory research · 2021
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In participants with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), there was a significant reduction of Cough Assessment Test score in Hydrogen/oxygen group compared to control (- 11.00 vs. – 6.00, p < 0.001). These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in participants with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). There was a significant reduction of Cough Assessment Test score in Hydrogen/oxygen group compared to control (- 11.00 vs. – 6.00, p < 0.001).
What the Researchers Studied
The researchers studied participants with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). The study used a randomized, double-blind human clinical trial.
What Effects Did Molecular Hydrogen Have?
Eligible patients were randomly assigned (in a 1:1 ratio) to receive either hydrogen/oxygen mixture or oxygen therapy. There was a significant reduction of Cough Assessment Test score in Hydrogen/oxygen group compared to control (- 11.00 vs. – 6.00, p < 0.001). The authors concluded that the trial demonstrated that hydrogen/oxygen therapy is superior to oxygen therapy in patient with AECOPD with acceptable safety and tolerability profile.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was participants with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). The study used a randomized, double-blind human clinical trial.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.